Skip to main content

Market Overview

BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study

  • BioXcel Therapeutics Inc (NASDAQ: BTAIinitiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation.
  • The 20 subject-trial is designed to evaluate the safety, efficacy, and pharmacokinetics of BXCL501 in intensive care unit adult patients experiencing delirium-related agitation, including COVID-19 patients.
  • The primary endpoint is reducing agitation measured by at least a 2-point drop in agitation scale at two hours post-BXCL501 administration.
  • The secondary endpoint is the earliest time at which a 2-point drop is seen after BXCL501 administration.
  • An exploratory endpoint of this trial will be to determine the overall clinical improvement after drug administration.
  • Topline results from the study expected in the first quarter of 2022.
  • BXCL501 is an orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms.
  • Price Action: BTAI is up 1.3% at $57.72 in market trading hours on the last check Thursday.

Related Articles (BTAI)

View Comments and Join the Discussion!

Posted-In: Covid-19 delirium-related agitation Phase 2 TrialBiotech News Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at